drugset / Trial / NCT00130195

Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)

NCT00130195

Phase 2 Completed 100 enrolled Japan Adult Leukemia Study Group
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the clinical efficacy and safety of imatinib-combined chemotherapy on newly diagnosed BCR-ABL-positive ALL.

Timeline

Start
2002-09
Primary completion
2008-02
Completion
2008-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule
Background Cyclophosphamide Other / unclassified
Background Cytarabine Small molecule
Background Daunorubicin Small molecule
Background Dexamethasone Small molecule
Background Methotrexate Small molecule
Background Prednisolone Other / unclassified
Background Vincristine Small molecule